...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: New MD&A posted

In addition to apabetalone, we have commenced preclinical testing on other BET inhibitors in our library of compounds which demonstrate similar efficacy and potency on important markers of vascular inflammation, acute phase response, complement and coagulation. These compounds will be further analyzed and explored for their potential use in orphan disease indications. 

Share
New Message
Please login to post a reply